A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 39073252.
- Also identified by DOI 10.1002/hed.27887 and PMC identifier 11729999.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population. ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed. Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51-96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis. In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.
Medical subject headings
- Radiosurgery
- Esthesioneuroblastoma, Olfactory
- Neoplasm Recurrence, Local
- Nose Neoplasms